This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
by Ekta Bagri
ADMA vs. Takeda: surging Asceniv demand boosts ADMA, but Takeda's diversified portfolio and stronger returns make it the steadier pick now.
ADMANegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Reports Strong Phase III Diabetes Data for Children & Adolescents
by Zacks Equity Research
Novo Nordisk reports phase III teen study success for oral semaglutide, showing strong HbA1c reduction and paving the way for the first oral GLP-1 for youth.
NVOPositive Net Change CPRXPositive Net Change ANIPPositive Net Change INDVPositive Net Change
biotechs
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
by Zacks Equity Research
Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.
REGNNegative Net Change BIIBNegative Net Change SUPNPositive Net Change APLSNo Net Change
biotechs
Incyte Gears Up to Report Q1 Earnings: What Can Investors Expect?
by Zacks Equity Research
INCY heads into Q1 earnings with a $1.23 billion revenue view, driven by Jakafi, Opzelura, rising royalties and multiple new launches contributing to revenues.
NVSNegative Net Change NVOPositive Net Change LLYNegative Net Change INCYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
SNY & REGN's Dupixent Wins FDA Nod for Pediatric Use in Urticaria
by Zacks Equity Research
Sanofi wins FDA nod to expand Dupixent in kids aged 2-11 years, marking the first biologic for young patients with uncontrolled CSU.
REGNNegative Net Change SNYNegative Net Change CPRXPositive Net Change INDVPositive Net Change
biotechs
Altimmune Catalysts: 2026 Data Readouts and Financing Risks
by Deepanwita Sarkar Saha
ALT's 2026 hinges on pemvidutide, with key readouts, a phase III start, and funding strategy set to shape investor sentiment.
NVOPositive Net Change LLYNegative Net Change ALTNegative Net Change MDGLPositive Net Change
biotechs
Is Altimmune a Buy Before Phase III MASH Starts in 2026?
by Deepanwita Sarkar Saha
ALT heads into a high-stakes 2026 as pemvidutide drives key phase III and mid-stage catalysts that could reshape its valuation-or risk setbacks.
NVOPositive Net Change LLYNegative Net Change ALTNegative Net Change MDGLPositive Net Change
biotechs
ALT Stock: What Pemvidutide Means for MASH, AUD and ALD
by Deepanwita Sarkar Saha
Altimmune bets big on pemvidutide across MASH, AUD and ALD, but with one drug driving value, upcoming trials could make or break the story.
NVOPositive Net Change LLYNegative Net Change ALTNegative Net Change MDGLPositive Net Change
biotechs
SNY's Tzield Gets FDA Nod for Kids, Sarclisa SC BLA Faces Delay
by Zacks Equity Research
Sanofi wins FDA nod to expand Tzield's use to younger patients, while Sarclisa SC review faces delay with a new decision date set for July 2026.
SNYNegative Net Change CPRXPositive Net Change MGNXNegative Net Change INDVPositive Net Change
biotechs
SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?
by Zacks Equity Research
Spyre Therapeutics' stock rises 73% in a month after mid-stage data show strong efficacy and safety for SPY001 in ulcerative colitis, boosting investor optimism.
JNJNegative Net Change TAKNegative Net Change SYREPositive Net Change
biotechs medical pharmaceuticals